Multiple Sites Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 26, 2021
Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced the U.S. Food and Drug Administration (FDA) has removed its clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01, a gene therapy candidate for the treatment of Huntington’s disease (HD), and confirmed that the company may proceed with its planned Phase 1/2 clinical trial. The decision was made following a comprehensive review of the Chemistry, Manufacturing and Controls information previously submitted to the FDA. Voyager plans to initiate VYTAL, a Phase 1/2 clinical trial of VY-HTT01, this year. ....

United Kingdom , Omar Khwaja , Andre Turenne , Sheryl Seapy , Exchange Commission , Head Of Research , Voyager Therapeutics Inc , Development Of Voyager , Drug Administration , One Time Gene Therapy , Early Huntington , Multiple Sites Expected , Investigational New Drug , Voyager Therapeutics , Private Securities Litigation Reform Act , Institutional Review Boards , Annual Report , Oyager Therapeutics Receives Fda Clearance Of Ind Application For Gene Therapy Candidate Vy Htt01 Treatment Huntingtons Disease , ஒன்றுபட்டது கிஂக்டம் , ஓமர் குவஜா , ஆண்ட்ரே ட்யுரிந் , பரிமாற்றம் தரகு , தலை ஆஃப் ஆராய்ச்சி , வோயேஜர் சிகிச்சை இன்க் , வோயேஜர் சிகிச்சை , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,